|
|
 |
|
Viewing report
|
|
|
|
Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
Bioseeker, Oct 2010, Pages: 659
This report comprises defined and up to date development strategies for 155 cancer vaccine drugs within the portfolio of 99 investigators, from Ceased to Marketed. The report extensively analyses their 94 identified drug targets, organized into 91 drug target strategies, and assesses them in 42 different cancer indications. BioSeeker has applied its unique drug assessment methodology to stratify the cancer vaccine pipeline and discern the level of competition in fine detail.
Major Findings from this report:
- The identified competitive landscape of cancer vaccine drugs is split between the 46% which have unique drug target strategies and the other half which have head-to-head target competing vaccine drugs in 20 different clusters. The latter has a competing ratio which is almost two and half time higher than the comparable average of cancer vaccine drugs. Contributing to this fact is heavily utilized drug target strategies like: ERBB2, TERT and MUC1.
- Nine out of ten drug target strategies in Phase III development are new to cancer vaccine drugs, whereas the greatest number of new target strategies are found in Preclinical- and Phase II development.
- Protein and gene therapy are the dominating compound strategies of cancer vaccine drugs, which represent half of the entire pipeline. Cell therapy based cancer vaccines has the least unique target strategy portfolio compared to that of other compound strategies of cancer vaccine drugs.
- The highest numbers of described target strategies among cancer vaccine drugs are found in breast cancer, colorectal cancer, melanoma and prostate cancer. Cancer vaccine drugs are experiencing targeting competition in one out of every three cancer indications described, and more so in cervical cancer/dysplasia, prostate cancer, head and neck cancer and breast cancer.
- The highest number of described drug target strategies of cancer vaccine drugs belongs to Advaxis, Cancer Research Technology, Dendreon and Inovio. However, when looking at the highest number of developmental projects Celldex Therapeutics, Cell Genesys, Advaxis and Dendreon take the lead.
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:
- Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
- Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
- Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area strategies
- Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any cancer vaccine drug to ensure that the optimal market conditions exist by the time the product is commercialized.
Customers who bought this item also bought
A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market
Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
Drug Delivery in Cancer - Technologies, Markets and Companies
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
Commercializing Peptides in Cancer: The Faster Route to Consider Your Options and Position of Others
Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline
The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others
A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market
|
|
|
|
